Reactions 1680, p131 - 2 Dec 2017 Interstitial lung disease: 2 case reports In the POLARIS (Post-Launch All-patient- Registration Surveillance) study for safety investigation of gemcitabine and erlotinib, 2 patients were described [ages and sexes not stated], who developed interstitial lung disease (ILD) following treatment with gemcitabine [route not stated] and erlotinib [duration of treatment to reactions onsets not stated] for pancreatic cancer. Case 1: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related. Eventually, the ILD had recovered, but the patient experienced a sequela. Case 2: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m2 weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related [outcome not stated]. Author comment: "Outcomes of ILD events were . . . 1 patient (1.9%) had a sequela and the outcome was unknown for 1 patient (1.9%)." "After reviewing the POLARIS data, the ILD review committee recommended that patients with pancreatic cancer should be evaluated for the risk factors identified here prior to beginning GE treatment. During GE treatment. . .If ILD symptoms occur, discontinuation of GE is recommended." Furuse J, et al. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology 47: 832-839, No. 9, 24 May 2017. Available from: URL: http:// doi.org/10.1093/jjco/hyx075 - Japan 803284325 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera